IMW 2021 | BCMA-targeted BiTEs for multiple myeloma
Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, gives an overview of the use of B-cell maturation antigen (BCMA)-targeted T-cell redirectors, and discusses how these fit into the treatment landscape for myeloma. Prof. van de Donk talks on the anti–BCMA bispecific T-cell engager (BiTE) pacanlotamab, previously known as AMG 420, which first demonstrated the efficacy of BCMA-targeted T-cell redirectors, producing response rates of 70-80% in heavily pretreated populations. Prof. van de Donk also talks on the latest clinical data from immunoglobulin G (IgG)-like bispecific antibodies such as elranatamab and explains the toxicity profiles for each. Prof. van de Donk further comments on novel combinations with anti-CD38 antibodies and immunomodulatory imide drugs (IMiDs), as well as with other antibodies such as teclistamab and talquetamab. Finally, Prof. van de Donk discusses the role of chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of myeloma, highlighting pros and cons in comparison to BiTEs. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Niels van de Donk, MD, PhD, has received research support from Janssen Pharmaceuticals, AMGEN, Celgene, Novartis and BMS; and serves in advisory boards for Janssen Pharmaceuticals, AMGEN, Celgene, BMS, Takeda, Roche, Novartis, Bayer, and Servier.
